AUTHORS
Paola Ghione, MD, MS, Esther Drill, DrPH2, Rita Tavarozzi Jr, MD,PhD3, Darina Paulino4, Rahul Nayak, MD5, Toan Bui6, Auris O. Huen, MD, PharmD7, Neha Akkad, MD8, Tarsheen Sethi, MD9, Haris Qureshi, MD10, Marcus Watkins, PhD11, Eric Mou, MD12, Anne Beaven, MD13, Cesar Virgen, MD, PhD14, Robert Stuver, MD15, Zachary Epstein-Peterson, MD16, Ellie Casper17, Melissa Pulitzer, MD18, Alison Moskowitz, MD19, Jasmine Zain, M.D.20, Neha Mehta-Shah, MD, MSCI21, Francine Foss, MD22, Swaminathan P. Iyer, MD23, Sima Rozati, MD PhD24, Steven Horwitz, M.D.25, Shamir Geller, MD26, Colin Begg27, Pamela Allen, MD28
AFFILIATIONS
1 Memorial Sloan Kettering Cancer Center, NEW YORK CITY, United States
2 Memorial Sloan Kettering Cancer Center, NEW YORK CITY, United States
3 Memorial Sloan Kettering Cancer Center, NEW YORK CITY, United States, University of Eastern Piedmont, Alessandria, Italy
4 Emory Winship Cancer Institute, Atlanta, United States
5 Emory Winship Cancer Institute, Atlanta, United States
6 Johns Hopkins Medicine, Baltimore, United States
7 Md Anderson Cancer Center, Houston, United States
8 Md Anderson Cancer Center, Houston, United States
9 Yale Cancer Center, New Heaven, United States
10 Yale Cancer Center, New Heaven, United States
11 Washington University, St Louis, United States
12 University of Iowa, Iowa City, United States
13 University of North Carolina, Chapel Hill, United States
14 Memorial Sloan Kettering Cancer Center, NEW YORK CITY, United States
15 Memorial Sloan Kettering Cancer Center, NEW YORK CITY, United States
16 Memorial Sloan Kettering Cancer Center, NEW YORK CITY, United States
17 Memorial Sloan Kettering Cancer Center, NEW YORK CITY, United States
18 Memorial Sloan Kettering Cancer Center, NEW YORK CITY, United States
19 Memorial Sloan Kettering Cancer Center, NEW YORK CITY, United States
20 Memorial Sloan Kettering Cancer Center, NEW YORK CITY, United States
21 Washington University, St Louis, United States
22 Yale Cancer Center, New Heaven, United States
23 Md Anderson Cancer Center, Houston, United States
24 Johns Hopkins Medicine, Baltimore, United States
25 Memorial Sloan Kettering Cancer Center, NEW YORK CITY, United States
26 Memorial Sloan Kettering Cancer Center, NEW YORK CITY, United States
27 Memorial Sloan Kettering Cancer Center, NEW YORK CITY, United States
28 Emory Winship Cancer Institute, Atlanta, United States
ABSTRACT
Background: Cutaneous T-cell lymphomas (CTCL), including mycosis fungoides (MF) and Sézary syndrome (SS), are heterogeneous malignancies with a wide spectrum of presentations, ranging from skin-limited disease that rarely requires systemic treatment to advanced disease with poor outcomes. Contemporary data on causes of death in large cohorts, that include non-White patients (pts) are limited. This retrospective study aims to characterize causes of death (COD) and early survival outcomes in a large, multi-institutional CTCL cohort.
Methods: We retrospectively analyzed 2,415 pts with CTCL from MSKCC and a multi-institutional BEACON-CTCL (Building Equitable and Collaborative Oncology network in CTCL) registry, including Emory, Hopkins, MDACC, Yale, WashU, U Iowa, and UNC. COD were harmonized across institutions and grouped as lymphoma(lym)-related (progressive disease, treatment-related), non-lym-related, or unknown. Unclear COD were reviewed by at least 2 physician-experts in CTCL. Deaths with unknown cause were recategorized as lym-related if the patient was in disease progression at the last follow-up. Survival estimates at 3 and 5 years were calculated excluding patients with missing stage and shorter follow-up. Comparisons used the log-rank test, chi-squared test, Fisher’s exact test, and the Kruskal–Wallis test.
Results: Median age at diagnosis was 58 years (43-69); 54% were male, 34% Black or African American (AA). Overall, 2090 (87%) had MF, 271 (11%) had SS, 54 (2%) had other CTCL subtypes. Sixty-nine % presented with limited-stage (1A–2A) CTCL. Median follow-up was 5.5 years (IQR 2.3, 9.3), reflecting a predominant early mortality capture. Among 760 deaths, 610 (80%) were attributed a known COD; 419 (55% of deaths; 68% of known causes) were lym-related. Among the 191 known non-lym-related deaths, 7 were cardiac, 24 were due to infection (2 COVID), 4 were secondary to treatment of other diseases, 38 were due to second cancers, 115 were due to other degenerative diseases or natural deaths for old age, and 3 were other COD. Of the 419 known lym-related deaths, 284 were due to disease progression, 2 were treatment-related cardiac, 76 were due to infectious complications of treatment, 8 for treatment toxicity (2 GVHD post AlloSCT), 4 for therapy-related MDS, and 45 died with disease progression however, the cause was not defined. At 3 and 5 years from diagnosis, lym-related deaths were 65%, and 60% of all deaths, respectively. Lym-related death was associated with advanced stage (65% advanced-stage vs 34% of early-stage deaths; p<0.001) and transformation (71% lym-related in transformed vs 19% lym-related in non-transformed; p<0.001). Of note, unknown causes of death were higher in patients with early-stage CTCL at diagnosis (25% vs 16% in advanced stage, p<0.001), with a total of 191 (60%) of the cases dying of non-lym-related and unknown COD. Of 136 stage 1-2A pts who died of lym-related causes, 119 (87.5%) had progressed to higher-stage (median highest stage reached: 3a), 46 (34%) had undergone transformation of disease, with some obvious overlaps. Pts dying of lym-related causes were younger at death (68 vs 74 years; p<0.001). Race was associated with cause of death, with AA pts dying of lym-related causes in 62% and non-lym-related in 21% vs 50% and 28% of white pts (p=0.007). Five-year est. survival was 80% (95% C.I. 78%, 82%) for MF versus 56% (50%, 62%) for SS (p<0.001), and 88% (86%, 90%) for early-stage versus 56% (52%, 60%) for advanced-stage (p<0.001). Males had inferior 5-year est. survival compared with females (74% (71%, 77%) vs 80% (78%, 83%); p=0.001).
Conclusions: In this large multi-institutional CTCL cohort, early mortality is predominantly lym-related, with advanced-stage and LCT highly associated with early lym-related deaths. Racial differences suggest that AA pts are at higher risk of lym-related early death. Early-stage disease patients mostly died of non-lymphoma-related or unknown causes (60%), unless their disease transforms or progresses. Results might reflect referral bias towards sicker patients referred to our academic centers. Next steps include expanding the cohort to include patients diagnosed up to the year 2000, to further analyze later COD.
DISCLOSURES
Paola Ghione, MD, MS: ADC Therapeutics - Consultancy (Includes expert testimony); AbbVie - Consultancy (Includes expert testimony); Regeneron Pharmaceuticals, Inc - Consultancy (Includes expert testimony)